Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

Immunotherapy, or antibody treatment that activates the patient’s own immune system against cancer, is increasingly being ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...